Thus, CCDC6 and USP7 might represent novel predictive biomarkers for the combined treatment of the USP7 inhibitors and PARP inhibitors in both hormone-sensitive and androgen-resistant prostate tumors. This evidence concerns the gene CCDC6 and prostate neoplasm.